The global enteral nutrition market size is estimated to total USD 3.67 Bn in 2026 and is projected to grow at a compound annual growth rate (CAGR) of 5.8% during the forecast period (2026-2033), reaching USD 5.45 Bn by 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 3.67 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
5.80% |
2033 Value Projection: |
USD 5.45 Bn |
Enteral nutrition refers to delivery of food containing carbohydrates, proteins, water, fat, minerals, and vitamins in the body using gastrointestinal tract with the help of feeding tubes. It is imperative for patients having functional gastrointestinal tract however are, unable to maintain a safe or adequate oral intake. Furthermore, a tube placed in nose, is known as nasoenteral tube, where it passes through the nasal cavity and into the stomach. However, when a tube passes through the skin into the stomach, it is called gastrostomy. Such tubes aid patients to ingest food, who are unable to consume normally.
Market Dynamics
Increasing incidence of chronic diseases such as cancer, diabetes, gastrointestinal disorder, and cardiovascular diseases, increasing novel product launch and approvals, and increasing adoption of growth strategies such as acquisition and collaboration by key players operating in the market are the important factors expected to drive the market growth over the forecast period. For instance, in September 2019, Nestle Health Science in collaboration with StartSe and R&D manufacturing specialists launched 'Nestle Beyond Food', a nutrition-based health program. Through this program, Nestle selected Brazilian startup businesses it wished to work with based on their business execution, nutritional support for outpatient, nutritional product solutions, and e-Health technologies.
Moreover, in March 2017, B. Braun Medical Ltd., launched a new range of nutritionally complete dietary drinks - Nutricomp Drink Plus. It is available in four flavors; the high-energy milkshake style supplement can be prescribed for the dietary management of malnutrition and can also be administered by tube in critically weak patients.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global enteral nutrition market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Abbott Laboratories, Nestle S.A., Danone S.A., Fresenius Kabi AG, Mead Johnson & Company, LLC, B. Braun Melsungen AG, Otsuka Pharmaceutical Co., Ltd, Meiji Holdings Co., Ltd., Bahrain Pharma, Bionova Lifesciences, Global Health Products Inc., Victus Inc., and Curtis Health Caps SP
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global enteral nutrition market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global enteral nutrition market
Market Segmentation
- By Product Type Insights (Revenue, US$ Bn, 2021 - 2033)
- Standard Enteral Nutrition
- Enteral Nutrition for Chronic Illness
- By Nutrition Type Insights (Revenue, US$ Bn, 2021 - 2033)
- Proteins
- Carbohydrates
- Multi-vitamins and Antioxidants
- Amino Acid
- Fibers
- Minerals
- Others
- By Formulation Insights (Revenue, US$ Bn, 2021 - 2033)
- By Patient Type Insights (Revenue, US$ Bn, 2021 - 2033)
- Adult
- Pediatrics
- Geriatrics
- By Application Insights (Revenue, US$ Bn, 2021 - 2033)
- Cancer
- Gastrointestinal Diseases
- Diabetes
- Critical Care
- Others (Nutrition Deficiency, etc.)
- By Distribution Channel Insights (Revenue, US$ Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By End User Insights (Revenue, US$ Bn, 2021 - 2033)
- Hospitals
- Home Care Settings
- Retirement Homes
- Others
- By Region Insights (Revenue, US$ Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Abbott
- Nestle S.A.
- Danone S.A.
- Fresenius Kabi AG
- Mead Johnson & Company, LLC
- Braun Melsungen AG
- Otsuka Pharmaceutical Co., Ltd
- Meiji Holdings Co., Ltd.
- Bahrain Pharma
- Bionova Lifesciences
- Global Health Products Inc.
- Victus Inc.
- Curtis Health Caps SP